Drug profile · INN
belumosudil
REZUROCK
belumosudil (REZUROCK) is a rho-associated protein kinase inhibitor.
EMA: approved Antineoplastic and immunomodulating agents (L04) L04AA48
Patents linked 2
Pipeline programs 3
News articles 0
Drug details — belumosudil
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 2
- Programs
- 3
- Data quality
- 0.83
Quick answer
belumosudil (REZUROCK) is a rho-associated protein kinase inhibitor.
Key facts
INN belumosudil
Brand REZUROCK
Mechanism Rho-associated protein kinase inhibitor
Target Rho-associated protein kinase 2
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AA48
Mechanism of action
Rho-associated protein kinase inhibitor
Primary target: Rho-associated protein kinase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is belumosudil?
belumosudil (REZUROCK) is a rho-associated protein kinase inhibitor.
What is the brand name for belumosudil?
REZUROCK is a marketed brand name for belumosudil. Check FDA Drugs@FDA for the current US label holder and prescribing information.